Natural History of Levodopa-Induced Dyskinesia (LID)

• Status: Withdrawn
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias (LID). The severity of these movements can range from subtle to extremely debilitating. These movements may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. Current estimates of the occurrence rate of LID range from 12 % to 100% after one year of levodopa treatment. These estimates used reporting mechanisms such as self-report and doctor-reported. These reporting mechanisms are not reliable. We will use an objective measure of dyskinesia in the first 5 years of treatment for Parkinson's disease. The purpose of this protocol is to use an objective measure to estimate dyskinesia onset.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Oregon Clinical and Translational Research Institute
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Diagnosis of Parkinson's disease

• At least 21 years of age

• Levodopa treatment that will be orally initiated no more than 1 month after the screening visit for the study.

Exclusion Criteria:

• Unable to stand for 1 minute intervals

• Sensory deficits in the feet

• Significant cognitive impairment

• Unstable medical or psychiatric conditions (including hallucinations)

• History of dopamine receptor blocking medications (Haldol, Orap, Zyprexa)